Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Researchers in pediatric oncology identified a powerful new drug with unparalleled strength against neuroblastomas that resist treatment with crizotinib.
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself. But a team of surgeons is in the nascent stages of developing a more targeted method for delivering chemotherapy, with lower toxicity.
In the first clinical trial of difluoromethylornithine (DFMO), an investigational agent for children suffering from neuroblastoma, side effects were minimal and patients saw long-term survival.
Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.
First approval for a therapy aimed specifically to treat the rare pediatric cancer
A promising target for developing new therapies for children with high-risk neuroblastoma has been found.
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to the drugs that target these mutations.
US and Australian Researchers Form Alliance to Facilitate Development of Treatments for Childhood CancersJune 03, 2014
Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer.
Tumor biology-based therapy offers excellent outcomes among children with intermediate risk neuroblastoma, according to results from a prospective phase 3 reduction of therapy study.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.
The important role of microRNAs in regulating neuroblastoma development has been unveiled by new research.
Proton therapy offered the optimal combination of target coverage and organ-sparing in a recent study involving children with high-risk neuroblastoma.
A new genomic approach for screening compounds has identified a compound that causes neuroblastoma cells to differentiate. This new strategy screens for compounds that could inhibit tumor growth by causing cancer cells to differentiate.
The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study.
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
Neuroblastoma is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that these tumors are sensitive to a new class of drugs.
Complete remission was achieved in a 6-year-old boy with recurrent neuroblastoma. One year after his last dendritic cell treatment, the boy shows no evidence of disease.
Extent of first or best surgery has no impact on overall, event-free, progression-free survival.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Pediatric patients with neuroblastoma who have mutations in two genes, ARID1A and ARID1B, survive only a quarter as long as patients without the changes. This discovery could eventually lead to early identification of patients with aggressive neuroblastomas.
Identifying large-scale chromosomal damage through a whole-genome scan can help doctors choose the best option for treatment of neuroblastoma in children.
Childhood cancer survivors may need earlier colorectal cancer screening, especially if abdominal radiation was part of their treatment.
Crizotinib active in anaplastic large cell lymphoma; neuroblastoma; other tumors with ALK mutations.
Stratification by age at diagnosis shows more mutations found in children diagnosed at an older age.
People who underwent cancer therapy as children have a heightened risk of developing gastrointestinal (GI) complications later in life, a new study shows.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|